The British Journal of Rheumatology, Vol 36, 541-546, Copyright © 1997 by British Society for Rheumatology
Y Zhang, A Toivanen and P Toivanen
Lewis rats were injected i.v. with live Yersinia enterocolitica, resulting
in 1-2 weeks in an arthritis greatly resembling human reactive arthritis.
Starting on day 3, 5, 10 or 13 after the bacterial inoculation, the rats
were treated for 3 weeks with 20 mg/kg/day of ciprofloxacin. The
development of arthritis was completely prevented if the antibiotic
treatment was started on day 3. In a group of rats treated with
ciprofloxacin from day 5 onwards, 2/14 rats already showed mild arthritis
at the time when the treatment was started. Antibiotic treatment cured the
arthritis of these rats as well as that of one additional individual in
this group which developed arthritis. No later exacerbations occurred. If
the antibiotic treatment was started on day 10 or 13, i.e. at the time of
well-developed arthritis, no effect on arthritis was observed; rather,
increased faecal excretion of Yersinia occurred following the antibiotic
treatment. We conclude that experimental Yersinia reactive arthritis can be
cured by antibiotics introduced at an early phase of arthritic development.
Regarding acute human enterogenic arthritis, the decision on antibiotic
treatment is not a straightforward matter. Our experimental results
indicate that the earlier the treatment is started, the better the result,
whereas late treatments seem to favour bacterial persistence.
ORIGINAL PAPERS
Experimental Yersinia-triggered reactive arthritis: effect of a 3-week course of ciprofloxacin
Turku Immunology Centre, Department of Medical Microbiology, Turku University, Finland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T Yli-Kerttula, R Luukkainen, U Yli-Kerttula, T Mottonen, M Hakola, M Korpela, M Sanila, J Uksila, and A Toivanen Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis Ann Rheum Dis, September 1, 2003; 62(9): 880 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Laasila, L Laasonen, and M Leirisalo-Repo Antibiotic treatment and long term prognosis of reactive arthritis Ann Rheum Dis, July 1, 2003; 62(7): 655 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T Hannu, L Mattila, A Siitonen, and M Leirisalo-Repo Reactive arthritis following an outbreak of Salmonella typhimurium phage type 193 infection Ann Rheum Dis, March 1, 2002; 61(3): 264 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J A A Hoogkamp-Korstanje, H Moesker, and G A W Bruyn Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis Ann Rheum Dis, November 1, 2000; 59(11): 914 - 917. [Abstract] [Full Text]
|
|
|
|
|
|
T Yli-Kerttula, R Luukkainen, U Yli-Kerttula, T Möttönen, M Hakola, M Korpela, M Sanila, J Parviainen, J Uksila, R Vainionpää, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis Ann Rheum Dis, July 1, 2000; 59(7): 565 - 570. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Simelyte, M. Rimpilainen, L. Lehtonen, X. Zhang, and P. Toivanen Bacterial Cell Wall-Induced Arthritis: Chemical Composition and Tissue Distribution of Four Lactobacillus Strains Infect. Immun., June 1, 2000; 68(6): 3535 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, M. Rimpilainen, E. Simelyte, and P. Toivanen What determines arthritogenicity of bacterial cell wall? A study on Eubacterium cell wall-induced arthritis Rheumatology, March 1, 2000; 39(3): 274 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Toivanen Managing reactive arthritis Rheumatology, February 1, 2000; 39(2): 117 - 119. [Full Text] [PDF]
|
|